Electrocore ECOR 深 滬
已收盤 06-05 16:00:00 美东时间
8.72
-1.220
-12.27%
華盛通- 最 高9.99
- 今 開9.90
- 成交量 13.64万股
- 最 低 8.55
- 昨 收 9.94
- 總市值 7233.86万
- 52周最高 10.3659
- 市盈率 靜 --
- 換手率 1.64%
- 52周最低 4.16
- 委 比 -29.03%
- 總股本 829.57万
- 歷史最高 303.75
- 量 比 0.57
- 振 幅 14.49%
- 歷史最低 2.925
- 每 手 1
- 風險率 1.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多electroCore director Thomas J. Errico acquires $59,790 of common shares
electroCore director Thomas J. Errico acquires $59,790 of common shares electroCore director Thomas J. Errico reported acquiring 10,000 common shares in two open-market buys at USD 5.98 to USD 5.99. His direct beneficial ownership rose to 360,071 common shares. Disclaimer: This news brief was create
05-26 20:52
electroCore to present at LD Micro Invitational XVI Conference
electroCore to present at LD Micro Invitational XVI Conference electroCore will present at LD Micro Invitational XVI Conference on May 18, 2026, at Luxe Sunset Boulevard Hotel in Los Angeles. Presentation scheduled for 10:30 a.m. PT, with one-on-one investor meetings planned through day. Disclaimer:
05-09 08:00
electroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026
electroCore, Inc. will participate in the LD Micro Invitational XVI Conference on May 18, 2026, in Los Angeles. Joshua Lev, Interim President and CFO, will present and host meetings. The company focuses on non-invasive bioelectronic technologies for health and wellness, offering products like gammaCore® and Quell®. More details available at www.electrocore.com.
05-09 00:00
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
electroCore Q1 EPS $(0.59) Misses $(0.51) Estimate, Sales $9.584M Beat $9.012M Estimate
electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.51) by 15.69 percent. This is a 25.53 percent decrease over losses of $(0.47) per share from the
05-07 04:28
electroCore Announces First Quarter 2026 Financial Results
ElectroCore, Inc. reported Q1 2026 net sales of $9.6 million, a 43% year-over-year increase, driven by growth in VA prescription sales and Truvaga direct-to-consumer sales. The company also saw a 24% improvement in adjusted EBITDA loss to $2.3 million. Key highlights include VA prescription gammaCore revenue up 26%, Quell product line sales surpassing $1.0 million quarterly revenue, and Truvaga revenue growing 38% with improved marketing efficien...
05-06 20:05
electroCore TAC-STIM™ Named National Semifinalist in National Safety Council Work to Zero Challenge
electroCore's TAC-STIM, a non-invasive vagus nerve stimulation product, has been named a national semifinalist in the 2026 Work to Zero Safety Innovation Challenge by the National Safety Council. TAC-STIM aims to reduce workplace fatigue, a major safety risk, by improving attention and decision-making. The product, developed with the U.S. Air Force Research Laboratory, is currently used by multiple military commands. ElectroCore will present TAC-...
04-30 12:00
electroCore Announces Publication in Frontiers in Neuroscience Highlighting Benefits of Non-Invasive Vagus Nerve Stimulation in Patients with Mild Traumatic Brain Injury and PTSD
electroCore, Inc. announced the publication of new clinical findings in *Frontiers in Neuroscience* demonstrating the potential benefits of non-invasive vagus nerve stimulation (nVNS) in patients with chronic mild traumatic brain injury (mTBI) and comorbid post-traumatic stress disorder (PTSD). A post-hoc analysis of 35 patients showed significant reduction in overall symptom burden across cognitive, affective, and somatic domains. The findings c...
04-01 12:00
electroCore Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
ElectroCore, Inc. announced the appointment of Seth Abrams as VP of Sales and Michael Fox as Chief Operating Officer. They will receive 30,000 and 70,000 RSUs respectively, subject to vesting over three years. The company specializes in non-invasive bioelectronic technologies for health and wellness, including products for chronic pain management.
03-31 12:00
electroCore Announces Issuance Of Two New Additions To U.S. Patent Portfolio
U.S. Patent No. 12,208,263, entitled "Devices and Methods for Vagal Nerve Stimulation" was issued on January 28, 2026U.S. Patent No. 12,213,795, entitled "Devices and Methods for Remote Therapy and Patient Monitoring"
03-30 20:04
